Biotech Aspirant Hutchmed Sails Full Steam Toward Hong Kong Homecoming IPO
Company backed by billionaire Li Ka-shing secures cornerstone investors for more than half of its $600 million secondary listing in its home market Key points: • Hutchmed announces new approvals…
RELATED ARTICLES
-
NEWS WRAP: Hutchmed sells non-core asset to focus on cancer treatment
0013.HK HCM.US - Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
688062.SHG
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
